(Q24247646)

30 July 2017

1 reference

title

Anti-spasticity agents for multiple sclerosis (English)

1 reference

30 July 2017

0 references

Carolyn A Young

3

0 references

author name string

David Shakespeare

1

0 references

Mike Boggild

2

0 references

D T Shakespeare

1

1 reference

30 July 2017

C A Young

2

1 reference

30 July 2017

M Boggild

3

1 reference

30 July 2017

M Boggild

2

0 references

C Young

3

0 references

language of work or name

English

0 references

publication date

20 October 2003

0 references

1 January 2000

1 reference

Cochrane Database of Systematic Reviews

30 July 2017

2001

0 references

published in

1 reference

30 July 2017

issue

4

1 reference

30 July 2017

page(s)

CD001332

1 reference

Baclofen for spasticity in multiple sclerosis Double-blind crossover and three-year study

30 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001332

An antispasticity effect of threonine in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001332

Safety, tolerability, and efficacy of orally administered cannabinoids in MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001332

Baclofen, a new antispastic drug. A controlled, multicenter trial in patients with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001332

An evaluation of baclofen treatment for certain symptoms in patients with spinal cord lesions. A double-blind, cross-over study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001332

A comparison of dantrolene sodium and diazepam in the treatment of spasticity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001332

The quantitative evaluation of intravenous methocarbamol in the relief of spasticity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001332

A trial of brolitene in the treatment of spasticity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001332

The GABA-agonist progabide for spasticity in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001332

High-dose oral baclofen: experience in patients with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001332

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001332

Phenytoin and Chlorpromazine in the Treatment of Spasticity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001332

7 January 2021

4-aminopyridine in the treatment of patients with multiple sclerosis. Long-term efficacy and safety

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001332

7 January 2021

Relationship of the antispasticity effect of tizanidine to plasma concentration in patients with multiple sclerosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001332

7 January 2021

Treatment of Spasticity in Multiple Sclerosis With Dantrolene

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001332

7 January 2021

New diagnostic criteria for multiple sclerosis: guidelines for research protocols

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001332

7 January 2021

Treatment of spasticity with botulinum toxin: a double-blind study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001332

7 January 2021

Peripheral and central effect of baclofen on ankle joint stiffness in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001332

7 January 2021

A meta-analysis of clinical trials involving different classifications of response into ordered categories

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001332

7 January 2021

The effect of intrathecal baclofen on electrical muscle activity in spasticity

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001332

7 January 2021

Effect of cannabinoids on spasticity and ataxia in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001332

7 January 2021

Tizanidine--initial pharmacokinetic studies in patients with spasticity

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001332

7 January 2021

Clonidine in the treatment of spasticity in patients with multiple sclerosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001332

7 January 2021

Tizanidine in the treatment of spasticity

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001332

7 January 2021

[Optimized therapy of spastic syndrome by combination intrathecal baclofen with botulinum toxin]

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001332

7 January 2021

Reduction of spastic increased muscle tone in multiple sclerosis by the nonopioid analgesic flupirtine

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001332

7 January 2021

Short-term effects of intrathecal baclofen in spasticity

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001332

7 January 2021

Diazepam in the treatment of spasticity. A preliminary quantitative evaluation.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001332

7 January 2021

The action of a GABA derivative in human spasticity

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001332

7 January 2021

A comparison of baclofen and diazepam in the treatment of spasticity

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001332

7 January 2021

Antiparetic and antispastic effects induced by tizanidine in patients with spastic paresis.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001332

7 January 2021

Gabapentin effect on spasticity in multiple sclerosis: a placebo-controlled, randomized trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001332

7 January 2021

Intrathecal baclofen administration for control of severe spinal spasticity: functional improvement and long-term follow-up

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001332

7 January 2021

Gabapentin for relief of upper motor neuron symptoms in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001332

7 January 2021

Marihuana as a therapeutic agent for muscle spasm or spasticity

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001332

7 January 2021

Continuous intrathecal baclofen for severe spasticity

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001332

7 January 2021

The effect of baclofen on the transmission in spinal pathways in spastic multiple sclerosis patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001332

7 January 2021

Tizanidine versus baclofen in the treatment of spasticity in patients with multiple sclerosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001332

7 January 2021

Long-term intrathecal baclofen therapy in patients with intractable spasticity

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001332

7 January 2021

Intrathecal baclofen therapy for adults with spinal spasticity: therapeutic efficacy and effect on hospital admissions

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001332

7 January 2021

The effect of magnesium oral therapy on spasticity in a patient with multiple sclerosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001332

7 January 2021

Intrathecal baclofen for severe spinal spasticity

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001332

7 January 2021

Modulation of presynaptic inhibition and disynaptic reciprocal Ia inhibition during voluntary movement in spasticity

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001332

7 January 2021

Variability and reliability of the pendulum test for spasticity using a Cybex II isokinetic dynamometer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001332

7 January 2021

Gabapentin for relief of spasticity associated with multiple sclerosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001332

7 January 2021

The Use of Dantrolene Sodium in Disorders of the Central Nervous System

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001332

7 January 2021

Gaba derivative in spasticity. (Beta-(4-chlorophenyl)-gamma-aminobutyric acid, Ciba 34.647-Ba).

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001332

7 January 2021

The effect of Dantrium on spasticity in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001332

7 January 2021

A double-blind trial with baclofen (Lioresal) and diazepam in spasticity due to multiple sclerosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001332

7 January 2021

Mode of action of dantrolene sodium in spasticity

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001332

7 January 2021

Effect of symptomatic therapy on motor difficulties in quantitative measurements of voluntary power

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001332

7 January 2021

Dantrolene sodium in chronic spasticity of varying etiology. A double-blind study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001332

7 January 2021

The acute effect of the GABA-agonist, THIP, on proprioceptive and flexor reflexes in spastic patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001332

7 January 2021

The clinical effect of the GABA-agonist, progabide, on spasticity

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001332

7 January 2021

Effect of clorazepate in spasticity and rigidity: a quantitative study of reflexes and plasma concentrations

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001332

7 January 2021

The treatment of spasticity in multiple sclerosis: a double-blind clinical trial of a new anti-spastic drug tizanidine compared with baclofen

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001332

7 January 2021

Tizanidine versus baclofen in the treatment of spasticity in multiple sclerosis patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001332

7 January 2021

A double-blind study of L-threonine in patients with spinal spasticity

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001332

7 January 2021

Baclofen in the Treatment of Spasticity

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001332

7 January 2021

Comparison of dantrolene sodium and diazepam in the treatment of spasticity

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001332

7 January 2021

Double-blind comparison of single doses of DS103-282, baclofen and placebo for suppression of spasticity

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001332

7 January 2021

The assessment of drug treatment of spastic gait

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001332

7 January 2021

The effect of dantrolene sodium in relation to blood levels in spastic patients after prolonged administration

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001332

7 January 2021

Action of cyproheptadine in spastic paraparetic patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001332

7 January 2021

Intrathecal baclofen for long-term treatment of spasticity: a multi-centre study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001332

7 January 2021

Correlations between dose, plasma concentrations, and antispastic action of tizanidine (Sirdalud).

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001332

7 January 2021

Management of severe spasticity with intrathecal baclofen delivered by a manually operated pump

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001332

7 January 2021

Lasting reduction of severe spasticity after ending chronic treatment with intrathecal baclofen

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001332

7 January 2021

Botulinum toxin (Dysport) treatment of hip adductor spasticity in multiple sclerosis: a prospective, randomised, double blind, placebo controlled, dose ranging study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001332

7 January 2021

Managing severe lower limb spasticity in multiple sclerosis: does intrathecal phenol have a role?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001332

7 January 2021

Evaluation of baclofen (Lioresal) for spasticity in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001332

7 January 2021

Clonazepam, Baclofen and Placebo in the Treatment of Spasticity

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001332

7 January 2021

Oral Diazepam in the Treatment of Spasticity in Paraplegia a Double-Blind Trial and Subsequent Impressions

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001332

7 January 2021

Baclofen increases the soleus stretch reflex threshold in the early swing phase during walking in spastic multiple sclerosis patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001332

7 January 2021

The effects of the GABA agonist, baclofen, on sleep and breathing.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001332

7 January 2021

Multi-centre, double-blind trial of a novel antispastic agent, tizanidine, in spasticity associated with multiple sclerosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001332

7 January 2021

A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001332

7 January 2021

A review of the properties and limitations of the Ashworth and modified Ashworth Scales as measures of spasticity.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001332

7 January 2021

Prazepam in the treatment of spasticity: A quantitative double-blind evaluation

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001332

7 January 2021

The effect of dantrolene sodium on spasticity in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001332

7 January 2021

Botulinum toxin A for spasticity, muscle spasms, and rigidity

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001332

7 January 2021

Oxcarbazepine and spasticity: further observations

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001332

7 January 2021

Chronic intrathecal baclofen administration for control of severe spasticity

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001332

7 January 2021

Intrathecal baclofen for spasticity of spinal origin: seven years of experience

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001332

7 January 2021

Intrathecal baclofen for intractable spasticity of spinal origin: results of a long-term multicenter study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001332

7 January 2021

Chronic intrathecal delivery of baclofen by a programmable pump for the treatment of severe spasticity.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001332

7 January 2021

10.1002/14651858.CD001332

Identifiers

DOI

2 references

Consolidated OpenCitations Corpus – April 2017

30 July 2017

1 reference

Consolidated OpenCitations Corpus – April 2017

PMC publication ID

7028001

0 references

14583932

1 reference

Consolidated OpenCitations Corpus – April 2017

1 reference